Screening paediatric rectal forms of azithromycin as an alternative to oral or injectable treatment  by Kauss, Tina et al.
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The  aim  of  this  study  was  to identify  a candidate  formulation  for  further  development  of  a  home  or
near-home  administrable  paediatric  rectal  form  of a broad-spectrum  antibiotic  – specially intended  for
(emergency)  use  in  tropical  rural  settings,  in particular  for children  who  cannot  take  medications  orally
and  far  from  health  facilities  where  injectable  treatments  can  be given.  Azithromycin,  a broad-spectrum
macrolide  used  orally  or intravenously  for  the  treatment  of  respiratory  tract,  skin  and  soft  tissue  infec-eywords:
zithromycin
ntibiotic
ectal
ormulation
ioavailability
tions,  was  selected  because  of its pharmacokinetic  and  therapeutic  properties.  Azithromycin  in vitro
solubility  and  stability  in physiologically  relevant  conditions  were  studied.  Various  pharmaceutical  forms,
i.e.  rectal  suspension,  two  different  rectal  gels,  polyethylene  glycol  (PEG)  suppository  and  hard  gelatin
capsule  (HGC)  were  assessed  for in  vitro  dissolution  and  in  vivo  bioavailability  in the  rabbit.  Azithromycin
PEG  suppository  appears  to  be  a promising  candidate.
© 2012 Elsevier B.V. Open access under CC BY license.. Introduction
Antibiotics are generally available in oral or parenteral formu-
ations. A limitation of either route is that they may be unsuited in
hildren, especially those who cannot take oral medications and/or
ive in environments where injections may  not be immediately
vailable or would be unsafe – as it is often the case in rural areas
n developing countries with limited access to health facilities. In
hese conditions, the rectal route could be a valuable alternative
Ernest et al., 2007). The rectal route is non-invasive easy-to-use
nd can be applied to patients who are unable or unwilling to take
edications orally. Besides, it avoids at least partially the ﬁrst passffect, improves the stability of drugs undergoing gastro-intestinal
egradation, and allows the administration of unpleasantly tast-
ng or smelling drugs (Allen, 2008). Main compounding and
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Open access under CC BY license.manufacturing formulas of suppository formulations have been
compiled in Pharmaceutical Press’s recent edition on suppository
(Allen, 2008) and investigated antibiotic suppository formulations
reviewed (Bergogne-Bérézin and Bryskier, 1999). There are exam-
ples like malaria where pre-referral rectal administration is feasible
and saves lives (Gomes et al., 2009). Bacterial infections like pneu-
monia and meningitis take a heavy toll on children in the tropics,
particularly those under ﬁve years of age, and together cause over
one thousand DALYs (disability-adjusted life years, a measure of
potential future years lost due to poor health), which is compar-
atively more than HIV. The World Health Organization (WHO)
estimates that globally 363,000 and 735,000 HIV-negative children
under ﬁve years of age died in 2000 due to Haemophilus inﬂuen-
zae type b and Streptococcus pneumoniae infections, respectively. In
addition, an estimated 50 million cases of Bordetella pertussis and
300,000 deaths occur every year; case-fatality rates in developing
countries are estimated by the WHO  to be as high as 4% in infants
(WHO, 2012). These infections are prevalent in rural settings of the
tropical world, with poor access to health facilities – meaning that
diagnosis and treatment may  be delayed, putting children lives in
danger. Children who become progressively unwell will have no
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reatment in the vicinity, as they will no longer be able to take oral
edications, while injections may  be hours away as they are not
vailable outside medical facilities. This is when rectal formulations
ay  save lives.
In order to be used in rural settings, a product must be not
nly effective and safe, but also affordable and stable in tropi-
al climate. A possible candidate is azithromycin, a semi synthetic
cid-stable macrolide with an expanded spectrum and improved
harmacokinetic characteristics over older macrolides (Dunn and
arradell, 1996), thus allowing short, once daily regimens (Langtry
nd Balfour, 1998). Structurally related to erythromycin, it acts
y inhibiting protein synthesis by binding to the 50S subunit
f the bacterial ribosome, and covers Gram-positive and Gram-
egative bacteria (Champney and Miller, 2002; Peters et al., 1992;
wainston Harrison and Keam, 2007). Its primary indications
nclude Chlamydia and Mycoplasma infections, whooping cough
Bordetella pertussis) and Legionnaire’s disease and used instead of
enicillin in beta-lactam allergic individuals. Azithromycin is used
requently for the treatment of community-acquired acute respi-
atory infections. It appears to be more active against Haemophilus
nﬂuenzae than erythromycin and against some enteric Gram-
egative bacilli, although not generally indicated for the treatment
f Enterobacteriaceae.
Furthermore, mass oral azithromycin distribution is a key com-
onent of the WHO’s trachoma elimination program and has been
ssociated with a reduction in all-cause mortality (Coles et al., 2012;
orco et al., 2009; WHO, 2012). Azithromycin spectrum of activity
overs most bacteria responsible for the main causes of infants and
hildren morbidity and mortality. Pneumococcus remains suscep-
ible to azithromycin in most areas of Sub-Saharan Africa and in
sia. Azithromycin also proves effective against Salmonellae spp. in
sia (Ashley et al., 2011; Buchanan et al., 2010; Lubell et al., 2011).
Azithromycin is generally administered at 30 mg/kg over 3
3 × 10 mg/kg/day) or 5 (10 mg/kg/day + 4 × 5 mg/kg/day) days. A
ingle-dose regimen of azithromycin has recently been proposed
sing controlled release tablets (Gandhi et al., 2004) or extended
elease microspheres (Lo et al., 2009; Swainston Harrison and
eam, 2007). This regimen has been shown to be as effective as
he same dose administered over several days in experimental ani-
al  models (Girard et al., 2005). Currently, single administration
f 30 mg/kg azithromycin in paediatric patients with acute otitis
edia is approved in the USA (Pﬁzer, 2012).
Azithromycin absorption after oral administration is relatively
apid, inducing in 2 h a peak plasma concentration (Cmax) of
83 g/l and 224 g/l in children from 0.6 to 5 years and 6 to 15
ears respectively after 5 day regimen (10 mg/kg + 4 days 5 mg/kg).
Langtry and Balfour, 1998). The drug distributes well to infected
uids, tissues and intracellularly, where therapeutically-relevant
oncentrations are maintained long after plasma concentrations
ave diminished. The elimination half-life in children is 32 to 64 h
nd total body clearance is 4.5 to 5.4 l/h/kg, offering the conve-
ience of a short, once-daily regimen (Langtry and Balfour, 1998).
n adults, the absolute bioavailability of azithromycin 250 mg  oral
apsules has been estimated at 38% of the intravenous dose (Pﬁzer,
012).
While erythromycin suppositories have been studied in pae-
iatric patients (though no commercially-available product exists
oday to our knowledge), there is only one published study for
zithromycin reporting measurable but low (3.2%) rectal absorp-
ion (Bergogne-Bérézin and Bryskier, 1999). For erythromycin,
ectal bioavailability (28–54%) was found to depend on the age of
hildren (Stratchunsky et al., 1991)The aim of this project was to identify a suitable formulation of
zithromycin that would produce adequate plasma levels, cover the
ain paediatric bacterial infections, and be affordable and accept-
ble for use in tropical countries. These requirements limited us toarmaceutics 436 (2012) 624– 630 625
conventional liquid, solid or semi-solid forms. This article describes
the pharmaceutical screening of four different azithromycin rectal
forms, two  hydrogels, a carbopol gel and hydroxypropyl methyl
cellulose (HPMC) gel, hard gelatin capsule and a PEG suppository,
compared to intra-venous and rectal controls. For this purpose
several azithromycin rectal formulations were developed and eval-
uated for their bioavailability in rabbits.
2. Material and methods
2.1. Material
Azithromycin dihydrate was  a gift from Pﬁzer, France.
Zithromax® (Pﬁzer) was used as IV azithromycin formulation. For
all our experiments, commercially available azithromycin dihy-
drate was chosen, as the most stable form of azithromycin hydrates
(Gandhi et al., 2002).
Pharmaceutical excipients, namely PEG 1500 and PEG 4000
(Fagron, France), hydroxypropylmethylcellulose (HPMC) 4000
(Colorcon, Hollande), microcrystalline cellulose (Emcocel 90,
Cooper, France), colloidal silica (Aerosil 300, Cooper, France),
carbopol 974P NF (Noveon, OH), triethylamine (Sigma, France),
propylene glycol (Cooper, France), miglyol 812N (Inresa, France),
citric acid, NaOH and NaCl were of pharmaceutical grade. Chemi-
cals used for analysis (acetonitrile, ammonium formate, phosphate
buffer) were of analytical grade.
2.2. Azithromycin solubility and stability evaluation in in vitro
simulated rectal pH conditions
2.2.1. Azithromycin apparent solubility in 4 h at pH 7–9
An excess of azithromycin (about 250 mg  precisely weighted)
was introduced into 5 ml  of 50 mM phosphate buffer of pH 7.0,
8.0 or 9.0. After 4 h of magnetical stirring (600 rpm) at room tem-
perature in hermetically closed recipients, samples were ﬁltered
with nylon 0.22 m syringe ﬁlters and adequately diluted in mobile
phase before HPLC analysis.
2.2.2. Azithromycin solution stability at pH 7–9
200 ml of extemporaneous azithromycin solution was prepared
in 50 mM phosphate buffer pH 7.0, 8.0 or 9.0. After complete disso-
lution of azithromycin (room temperature ultrasounds 20 min) the
solutions were ﬁltered through syringe nylon ﬁlters of 0.45 m.  At
time T0, samples (n = 3, 10 ml)  were taken for T0 analysis and her-
metically closed vials containing the rest of solutions were placed at
37.0 ◦C. Further samples (n = 3, 10 ml)  were taken at T0 + 4 h, T0 + 8 h
and T0 + 24 h and analysed using HPLC (as shown in Section 2.3.2).
2.3. Azithromycin pharmaceutical formulations
2.3.1. Preparation of azithromycin formulations
All formulations tested except IV (Zithromax®, Pﬁzer) were
developed in our laboratory. The formulations were optimized for
their pharmacotechnical properties, compatibility with excipients
used and drug release properties. Table 1 summarizes ﬁnal formu-
lations considered.
Rectal suspension (formulation A) was prepared by dispersion
of azithromycin (sieved at <250 m)  in medium chain triglyceride
oil (miglyol 812N). Carbopol gel (formulation B) was prepared
by dispersion of azithromycin (<250 m)  and then Carbopol® in
propylene glycol/water mixture and neutralized using triethy-
lamine. HPMC gel (formulation C) was  prepared using HPMC as
mucoadhesive gelling excipient, by dispersion of azithromycin
(<250 m)  and then HPMC in water/ethanol mixture. Azithromycin
suspended suppositories (formulation D) were prepared by disper-
sion of azithromycin (<250 m)  in melted PEG mixture at 70 ◦C
626 T. Kauss et al. / International Journal of Pharmaceutics 436 (2012) 624– 630
Table  1
Galenic rectal formulations of azithromycin.
Formulation
A B C D E
Pharmaceutical form Suspension Carbopol gel HPMC gel Suppository Hard gelatin capsule
Dose  (mg/kg) 20 20 20 20 20
Dosage by Volume Mass Mass Mass Mass
Composition unit % (w/v) % (w/w) % (w/w) % (w/w) % (w/v)
Azithromycin 2H2Oa 2.1 2.1 2.1 16.2 80.48
Carbopol 974P NF – 0.8 – – –
Triethylamine – 0.8 – – –
HPMC 4000 – – 2.4 – –
Microcrystalline cellulose – – – – 19.21
Colloidal silica – – – – 0.31
PEG 1500 – – – 16.9 –
PEG  4000 – – – 67.7 –
Propylene glycol – 84.0 – – –
Miglyol 812N 97.9 – – – –
Ethanol (99%) – – 10.0 – –
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2.1 g and 16.2 g of azithromycin 2H2O is equivalent to 2.0 g and 15.4 g of anhydrou
water bath) and cooled at room temperature. All dispersions were
erformed under electrical stirring, which was maintained dur-
ng sampling for liquid and semi-liquid preparations. Azithromycin
GC were prepared using Turbula® (Erweka, France) powder
lender and semi-automatic HGC ﬁller and loader LGA QB 300 (LGA,
rance). All forms were prepared extemporaneously.
Pharmaceutical forms used for in vivo evaluation in rabbits were
djusted to animal weight and administered using 1 ml  syringe for
iquid and semi-liquid formulations and 1 ml  pipette like device for
ry forms.
In case of suppositories, the same formulation was  administered
o animals at 20 mg/kg and 40 mg/kg. All other tested formulations
ere administered at 20 mg/kg. Zithromax® at 10 mg/kg was used
s IV reference.
.3.2. In vitro evaluation of azithromycin formulations
Visual homogeneity, mean assay (n = 3) and dissolution tests
n = 6) were performed for all rectal formulations.
For azithromycin content, approximately 450 mg  of formula-
ion was precisely weighted and completed up to 20 ml  with HPLC
obile phase. After 60 min  of magnetical stirring at 600 rpm, the
reparation was ﬁltered at 0.22 m nylon syringe ﬁlters before
nalysis.
Dissolution tests (n = 6 for each formulation) were performed in
uropean pharmacopoeia apparatus 2 containing 250 ml  of phos-
hate 50 mM buffer pH 7.0 per bowl at 37.0 ◦C and 75 rpm. Rectal
iquid or semi-liquid formulations (A–C, approximately 6 g pre-
isely weighted formulation) were tested in dialysis membrane
ags (Spectra/Por® molecular porous membrane, diameter 25 mm,
WCO  12-14.000, Spectrum Laboratories, USA) and ballasted to
ssure their immersion. Samples (1 ml,  replaced with fresh disso-
ution medium) were taken at T0 and 15/30/45/60/90/120 min  with
0 m nylon pre ﬁlter and injected directly on HPLC system.
.3.3. HPLC analysis of azithromycin in vitro samples
HPLC analyses were performed on Waters HPLC system with
15 HPLC Pump, 717plus Autosampler and 2487 Dual  Absorbance
etector (Waters, France). Previously described HPLC method for
zithromycin determination was used (Gaudin et al., 2011). Brieﬂy,
 mixture methanol/phosphate buffer 15 mM (80:20, v/v) with
pparent pH of 9 was used as a mobile phase and ﬁltered on
ylon 0.22 m membrane ﬁlter before use. UV detection was set
t 210 nm and the ﬂow rate was set at 1 ml  min−1. 10 l of each
ample was injected. The column used was Luna C8 EC 5 m,85.5 – –
romycin respectively.
150 mm ×4.6 mm (Phenomenex, France) thermostated with Cro-
cocil oven (CIL, Saint Foy la Grande, France) at 20 ◦C.
2.4. Animal pharmacokinetic experimentation
Adult New Zealand White KBL rabbits were used for pharma-
cokinetic studies after at least 10 days of acclimation. Animals were
placed into individual cages in controlled temperature (17–21 ◦C)
and humidity (40–70%) room. They were fastened 12 h before start-
ing pharmacokinetic study, but had water ad libitum.
The administration of each formulation was  adapted individu-
ally to the rabbit body weight.
Blood samples (about 0.5 ml  of blood per time point) were col-
lected from peripheral ear vessels into heparinized plastic tubes
(opposite ear in case of IV administration), kept on an ice-water
bath, and then centrifuged (10 min, 1200 g, +4 ◦C). At least 200 l
of plasma was stored in a freezer at −80 ◦C until analysis. Blood
samples were collected at pre-dose, then 6 samples in 24 h post-
administration according to formulations.
Groups of three or four animals were used for pharmacokinetic
screening of azithromycin formulations for suppositories and other
formulations respectively.
Pharmacokinetic parameters, namely Cmax, Tmax and AUC of
each condition were obtained from each individual plasma proﬁle
and then mean and standard deviation (SD) were calculated. AUC
was calculated using trapezoid rule.
2.5. Pharmacokinetic sample preparation and LC–MS/MS
analysis conditions
Plasma proteins were precipitated by adding 200 l of methanol
to 10 l of plasma in a 96 well plate. After capping and vortex
mixing, the plate was  centrifuged for 15 min  at 2060 × g at 6 ◦C.
An aliquot of 150 l of supernatant was  transferred into a new
96 well plate and dried at 40 ◦C. Sample extract was reconstituted
with 150 l of a mixture solution of 10 mM ammonium formate pH
3.5/acetonitrile (50:50, v/v). After capping and vortex mixing, the
plate was centrifuged for 3 min  at 2060 × g at 6 ◦C and the super-
natant was  injected onto the LC–MS/MS system. Standards were
made with rabbit plasma using heparin as anticoagulant. 10 l of
each sample was injected.HPLC system was  Hewlett Packard 1100 series equipped with
autosampler CTC Analytics CTC PAL refrigerated at 10 ◦C. The
separation was performed with Zorbax SB-C8 4.6 mm ×75 mm,
3.5 m column. The mobile phase used was a gradient mixture of
T. Kauss et al. / International Journal of Ph
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Fig. 1. Variation within rectal physiological pH range of azithromycin apparent sol-
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oncentrations after 4, 8 and 24 h at 37 ◦C after dissolution (right, Y axis). Legend:
Z  = azithromycin.
0 mM ammonium formate pH 3.5 and acetonitrile (45/55%, v/v at
–1.7 min, 30/70% (v/v) at 1.8–2.5 min, 10/90% (v/v) at 2.6–3.5 min
nd 45/55% (v/v) at 3.6–5 min) with a total run of 5 min. The ﬂow
ate was set to 1.0 ml  min−1 and the column oven temperature
o 40 ◦C. In these conditions, the approximate retention time of
zithromycin was 2.02 min.
MS  instrument used was Perkin Elmer SCIEX API 3000 with
urbo ion spray ionization in positive ion mode. Azithromycin frag-
ents for MRM  transitions were m/z  375.25 and m/z  591.30. The
ower and the upper quantiﬁcation limits were determined to be
.00 and 2060 ng/ml respectively.
.6. Statistical analysis of data
In vitro obtained data were analysed using Student’s bilateral
aired t test. The difference is considered signiﬁcant for p < 0.05.
For in vivo data, the reduced number of experimental ani-
als rendered usual statistical biopharmaceutical (bioequivalence)
nalysis like ANOVA not appropriate. Mean ± SD values were given
or each result.
. Results and discussion
.1. Dissolution and stability of azithromycin in
hysiologically-relevant conditions
The dissolution of azithromycin hydrates is reportedly slow
Gandhi et al., 2002), requiring 48 h to reach equilibrium solu-
ility in water under 100 rpm stirring. For rectal administration,
zithromycin in situ dissolution was considered as a potential
bsorption-limiting factor. We  studied azithromycin apparent
olubility over clinically-relevant conditions for duration, temper-
ture and pH range. The rectal pH is reportedly near-neutral in
ealthy and unwell infants >28 days old (range 6.68–7.12) (Turner
t al., 2011), though more alkaline values (7.2–12.1) were found in
ne study in children (Jantzen et al., 1989).
After incubation at 37 ◦C for 4 h in phosphate buffer at pH 7–9
 log-linear decrease in azithromycin solubility was  found with
ncreasing pH (Fig. 1). This is consistent with azithromycin pKa val-
es (8.7 and 9.5) (Zhang et al., 2009): when pH < pKa, azithromycin
s protonated and consequently more soluble in water.
The second experiment aimed at verifying whether once
issolved, azithromycin remained stable. The experiment was
xtended to 24 h so as to exceed the usual residence time in rectum.
he azithromycin solution stability was better at basic than neutral
H. Azithromycin content (Fig. 1) remained >90% throughout the
4 h in all tested pH conditions (7–9) at 37 ◦C. Previous studies havearmaceutics 436 (2012) 624– 630 627
shown that at pH 8, the half-life of azithromycin in buffered solution
was 54 days at 20 ◦C and 6 days at 40 ◦C (Esteban et al., 2009).
The relative stability and apparent solubility performances of
azithromycin were deemed compatible with rectal administration.
3.2. Pharmaceutical development and in vitro evaluation
Several pharmaceutical forms, namely rectal gels, hard gelatin
capsules and suppositories, were developed for the purpose
(Table 1). The spectrum of pharmaceutical forms was  restricted by
our target product proﬁle, to opt that it would be inexpensive, could
withstand tropical conditions, is easy to use by children and deliv-
ered by untrained persons. Thus, novel technologies, e.g. nano- and
microtechnologies were not considered, as they would be unaf-
fordable. A series of assays was  performed to ensure the feasibility
and obtain correct pharmaco-technical performances. A muco-
adhesive gel was  tested in order to enhance rectal bioavailability by
increasing the residence time in situ as compared to classical non
muco-adhesive formulations. The content of the gelling agent (car-
bopol 0.6–1.0% (w/w) or HPMC 2.0–2.8% (w/w)) was adjusted to
adapt the thickness of the formulation to a possible administration
with a syringe. Soluble suppositories, based on PEG mixtures, were
preferred to fatty fusible suppositories as they have a higher melt-
ing point, thus not requiring special storage conditions. Previous
studies showed that the melting point increases and drug release
rate decreases with increasing PEG molecular weight (Leuner and
Dressman, 2000). The mixture of PEG used (1500 and 4000) pro-
vided for both a melting point >45 ◦C and relatively rapid drug
release.
The HGC formulation was  modiﬁed in terms of ﬂowability of the
powder mixture and in terms of homogeneity of the mixing process
by adding a colouring agent in feasibility batches. Colloidal silica
improved the ﬂowability whereas talc and magnesium stearate
did not. The minimal quantity of colloidal silica obtaining satis-
factory ﬂowability results was chosen for further evaluations. As
reference products we used a commercially available intra-venous
formulation (Zithromax®, Pﬁzer) and an oily rectal suspension.
Final formulations are summarized in Table 1.
The results of in vitro drug release tests of the ﬁnal formula-
tions are summarized in Table 2; azithromycin content was within
100 ± 5% for all formulations, while drug release after 45 and
90 min  varied according to the formulation. Rapid drug release
was observed for azithromycin PEG suppositories and azithromycin
HGC. The drug is released from PEG suppositories as a consequence
of the progressive dissolution of PEG in the surrounding liquid.
PEGs are known to increase both, drug dissolution and its solu-
bility, explaining enhanced drug release (Allen, 2008). For HGC, the
direct dissolution of small AZ particles (<250 m) with increased
contact surface allowed rapid drug release. Azithromycin HGC
released drug even more rapidly than PEG suppository (p < 0.01,
Student’s t test). Drug release studies of gels and oily suspension
of azithromycin, contrary to HCG and suppositories, required the
use of dialysis bags, making results not directly comparable. Of
note, azithromycin suspension in dialysis bags gave comparable
results (20–30% in 90 min) as others available in the literature for
free drug (Arora et al., 2010). Carbopol azithromycin gel released
signiﬁcantly more azithromycin (p < 0.05, Student’s t test) than con-
trol oily suspension at 45 and 90 min. Drug release from HPMC
gel was sustained compared to carbopol gel and statistically not
different from the control suspension (p > 0.10, Student’s t test).
Overall, the rate of drug release was  low from gels (viscosity reduc-
ing the dissolution rate and hampering the diffusion of dissolved
azithromycin fractions towards dissolution medium) and oily sus-
pension (indirect mechanism of release: dissolution in oily phase,
diffusion towards interface, partition between aqueous and oily
medium) (Table 2).
628 T. Kauss et al. / International Journal of Pharmaceutics 436 (2012) 624– 630
Table  2
In vitro evaluation of azithromycin rectal formulations.
Azithromycin formulation
A B C D E
Azithromycin content (mean ± SD, n = 3) 100.8 ± 4.1 102.9 ± 2.3 99.5 ± 2.0 98.3 ± 0.9 100.3 ± 1.2
Drug  release at 45 min  (mean ± SD, n = 6) 5.5 ± 0.8 13.4 ± 7.9* 5.5 ± 0.5 73.8 ± 1.8** 88.0 ± 16.4**
Drug  release at 90 min  (mean ± SD, n = 6) 22.8 ± 10.3 29.5 ± 19.4 14.0 ± 6.0 98.9 ± 1.4** 88.3 ± 9.5**
Legend: A = azithromycin rectal suspension (rectal reference); B = azithromycin carbopo
HGC;  *p < 0.05 Student’s t test compared to formulation A; **p < 0.01 Student’s t test comp
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The long term ICH stability studies were outside the scope of our
reliminary project, and are planned only for the ﬁnal, biopharma-
eutically optimized formulation. Nevertheless, suppositories and
ard gelatine capsules were kept in ambient condition in plastic
oulds or closed glass bottle respectively. Samples were periodi-
ally analysed by HPLC for their drug content. Suppositories were
table (95–105% AZ content) after 2 years and hard gelatine cap-
ules after 6 months (end of study). In view of in vitro and in vivo
rug release data, gel’s stability was not analysed further.
.3. In vivo bioavailability screening of azithromycin
ormulations
Azithromycin rectal formulations were tested in rabbits at
0 mg/kg and compared to IV (10 mg/kg) and to a fatty suspen-
ion of azithromycin (formulation A, 20 mg/kg) used as rectal route
eference. Doses were determined based on previously published
nimal pharmacokinetic data (Shepard and Falkner, 1990). Fig. 2
able 3
harmacokinetic parameters of various azithromycin formulations (IV, A–E) in rabbits (m
Pharmacokinetic
parameter
Formulation
IV A 
Cmax (ng/ml) 2251 ± 696 171 ± 37 
Tmax (h) 0.08 ± 0.00 0.50 ± 0.31 
AUC0–24 h (ng h/ml) 2475 ± 648 603 ± 171 
(AUC0–24 h × IV dose)/
(AUC0–24 h IV × dose x)
100 12.2 
(AUC0–24 h × dose A)/
(AUC0–24 h A × dose x)
– 100 
egend: A = azithromycin rectal suspension (rectal reference); B = azithromycin carbopo
GC;  x = studied formulation (IV or A–E).l gel; C = azithromycin HPMC gel; D = azithromycin suppository, E = azithromycin
ared to formulation A.
shows rabbit plasma proﬁles of rectally administered formulations
and Table 3 summarizes the main pharmacokinetic parameters.
Azithromycin rectal absorption was rapid for the suspension
and carbopol gel (Tmax 15 min), while it required 30 min to reach
maximum plasma concentration for the HGC and 60 min for the
HPMC gel and the PEG suppository. These results are in line
with in vitro dissolution data. The highest rectal Cmax and rec-
tal AUC0−24 h was  obtained with the PEG suppository; relative
bioavailability was  ∼28% of IV and ∼2.3 times that of the rec-
tal suspension. All other formulations produced similar exposures
between 11–16% of IV and 90–129% of rectal suspension (as shown
in AUC0−24 h, Table 3).
The ratios AUC24 h/minimum inhibitory concentration
(MIC) and Cmax/MIC are regarded as the main pharmacoki-
netic/pharmacodynamic parameters for azithromycin efﬁcacy.
Differently from erythromycin, for azithromycin the AUC24 h/MIC
is more important than T/MIC because of its long half-life and
good tissue penetration (Van Bambeke and Tulkens, 2001). Of  the
formulations tested, the PEG suppository appears to be the most
promising candidate, but has a potential shortcoming – the rather
long Tmax, which is of particular concern if early onset of action is
needed.
The suspended PEG suppository is a prototype and will require
further, biopharmaceutical optimization work. The 28% bioavail-
ability relative to IV is an encouraging result compared to 38% for
the existing oral formulation (extrapolated 75% relative bioavail-
ability of suppositories compared to oral capsules). While values in
humans cannot be directly inferred from (limited) animal data, our
results are within the range of values described in the literature in
terms of Cmax, namely 2400 ng/ml after 10 mg/kg azithromycin IV
dose in children (Jacobs et al., 2005), 400–500 ng/ml after 500 mg
azithromycin oral dose in adults (Boonleang et al., 2007; Gandhi
et al., 2004) and 318 ng/ml after 12 mg/kg oral dose in children
(Stevens et al., 1997). The bioavailability of the suppository formu-
lation could be further improved by adding absorption enhancers
or using a eutectic mixture of PEG and azithromycin. The princi-
ples used to improve drug solubility for oral delivery (Shepard and
Falkner, 1990) could be applied to rectal formulations.
It should be noted that, due to the ethical requirement to
minimize the number of animal tested and the relatively high
ean ± SD).
B C D E
215 ± 157 59 ± 11 261 ± 228 89 ± 11
0.25 ± 0.00 3.50 ± 2.50 1.67 ± 0.94 0.83 ± 0.12
546 ± 308 779 ± 107 1400 ± 919 646 ± 293
11.0 15.7 28.3 13.1
90.6 129.1 231.9 107.1
l gel; C = azithromycin HPMC gel; D = azithromycin suppository, E = azithromycin
T. Kauss et al. / International Journal of Ph
Table  4
Comparison of pharmacokinetic parameters of 20 mg/kg (D20) and 40 mg/kg (D40)
azithromycin suppository administration in rabbits (mean ± SD n = 3).
Formulation D20 D40 D40/D20 ratio
Azithromycin dose (mg/kg) 20 40 2
Cmax (ng/ml) 261 ± 228 255 ± 203 1.0
Cmax/Dose (ng/ml/mg/kg) 13.1 6.4 0.5
c
e
m
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t
r
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A
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r
nTmax (h) 1.67 ± 0.94 1.67 ± 0.94 1
AUC0–24 h (ng h/ml) 1400 ± 919 2026 ± 1328 1.5
oncentrations still persisting 24 h post-dosage (C24 h ≈ 1/10Cmax
xcept for HPMC gel C24 h > 1/10Cmax), it was not possible to esti-
ate correctly AUC0–∞.
Even though rectal tolerance studies were beyond the scope
f the current screening work, no signiﬁcant change in rabbit
ehaviour was evidenced that could be ascribed to tolerability
ssues, nor was the presence of blood at the anal sphincter with
ny of the formulations.
.4. Dose-dependence of azithromycin PEG suppositories
The effect of azithromycin dose on exposure is reported in
able 4. Pharmacokinetic parameters did not vary proportion-
lly with the dose of azithromycin administered. Cmax remained
nchanged for 20 and 40 mg/kg of azithromycin (261 and 255 ng/ml
espectively) and the extrapolated AUC value ratio was  1:1.5
ompared to 1:2 ratio for the azithromycin dose. Tmax remained
nchanged.
Again, caution should be applied when interpreting these
esults, both because of the small number of experimental ani-
als and because plasma concentrations may  not reﬂect the true
otal exposure in peripheral compartments. While both plasma and
issue concentrations were reportedly increased when doubling
zithromycin dose from 500 to 1000 mg  per os in healthy adults
Danesi et al., 2003), an oral dose of 20 mg/kg produced only a
arginal increase in plasma AUC over 10 mg/kg (AUC ratio 1:18),
ut a more signiﬁcant increase of tonsil tissue AUC (AUC ratio 1:53)
Blandizzi et al., 2002). Future studies with improved formulations
hould allow extended sampling time and ideally measure tissue
evels as well as plasma concentrations.
. Conclusion
An azithromycin suspended PEG suppository was identiﬁed as a
romising candidate for further pharmaceutical development with
he aim of achieving comparable bioavailability to the oral route.
uch formulation would be an easy-to-use, safe and cheap alterna-
ive to oral and injectable forms. While the reason for developing a
ectal form was primarily intended for near-home emergency use
n rural settings of developing countries, a PEG suppository of a
road-spectrum antibiotic would also be a useful addition to the
urrent paediatric therapeutic armory.
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